BridgeBio Pharma, Inc. Research and Development Expense of Revenue

Research and Development Expense of Revenue of BBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development Expense of Revenue for the quarter ending September 30, 2022 was 27370.12% (a 18520.4% increase compared to previous quarter)
  • Year-over-year quarterly Research and Development Expense of Revenue increased by 2786.17%
  • Annual Research and Development Expense of Revenue for 2021 was 646.94% (a -84.17% decrease from previous year)
  • Annual Research and Development Expense of Revenue for 2020 was 4085.91% (a 689.36% increase from previous year)
  • Annual Research and Development Expense of Revenue for 2019 was 517.62% (a Infinity% increase from previous year)
  • Twelve month Research and Development Expense of Revenue ending September 30, 2022 was 485.83% (a -0.46% decrease compared to previous quarter)
  • Twelve month trailing Research and Development Expense of Revenue decreased by -24.9% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
485.83% 488.09% 614.7% 646.94%
Visit stockrow.com/BBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development Expense of Revenue of BridgeBio Pharma, Inc.

Most recent Research and Development Expense of Revenueof BBIO including historical data for past 10 years.

Interactive Chart of Research and Development Expense of Revenue of BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 27370.12% 146.99% 6354.72%
2021 948.32% 4449.87% 188.73% 26527.92% 646.94%
2020 73913.11% 1132.64% 0.0% 0.0% 4085.91%
2019 415.99% 206.72% 0.0% 0.0% 517.62%
2018 0.0% 0.0%
2017 0.0%

Business Profile of BridgeBio Pharma, Inc.

Sector: Healthcare
Industry: Biotechnology